GlassScriptPhysician profile
Caitlin M Flis
NPI 1023585031
$2,853.11
in general payments reported to CMS, 2019-2025
30 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $800 · 2022: $932 · 2023: $410 · 2024: $421 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $412.21 | 2021-2025 | Belbuca, Xtampza |
| Abbvie INC. | $383.32 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $381.14 | 2021-2024 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.92 | 2021-2024 | Relistor |
| Almatica Pharma LLC | $170.88 | 2021 | |
| Nevro Corp. | $170.23 | 2022-2024 | Senza |
| Boston Scientific Corporation | $131.74 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept |
| Amgen INC. | $121.76 | 2021-2022 | |
| Nalu Medical, INC. | $90.44 | 2022-2024 | Nalu Neurostimulation System |
| Vertex Pharmaceuticals Incorporated | $76.16 | 2025 | |
| Lilly USA, LLC | $55.01 | 2021-2022 | |
| Novo Nordisk INC | $46.07 | 2025 | Ozempic, Wegovy |
| Redhill Biopharma INC. | $42.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $37.14 | 2025 | Airsupra |
| Medtronic, INC. | $37.04 | 2022-2023 | Intellis Adaptivestim |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $33.56 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $33.41 | 2021 | |
| Radius Health, INC. | $33.40 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $32.28 | 2021 | |
| Allergan, INC. | $31.91 | 2021 | |
| Grt US Holding, INC. | $30.90 | 2021-2022 | |
| Uswm, LLC | $28.09 | 2021 | |
| Stimwave Technologies Incorporated | $25.94 | 2021 | |
| Orexo US, INC. | $24.00 | 2025 | Zubsolv |
| Exact Sciences Corporation | $20.06 | 2025 | The Cologuard Plus Collection Kit |
| Alk-Abello, INC | $19.11 | 2025 | Neffy |
| Pfizer INC. | $18.87 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $16.36 | 2021 | |
| West Therapeutics Development, LLC | $15.07 | 2021 | |
| Relievant Medsystems, INC. | $14.82 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Flis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.